Ligand Pharmaceuticals Incorporated (LGND)Healthcare | Biotechnology | Jupiter, United States | NasdaqGM
231.82 USD
+8.58
(3.843%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 231.73 -0.09 (-0.087%) ⇩ (April 17, 2026, 5:48 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:06 p.m. EDT
LGND is showing mixed signals for short-term and long-term investors. The recent price movement has been volatile, with a recent dip and a rebound. The fundamentals indicate a high-risk profile, with a high debt-to-equity ratio and a high overall risk rating. The lack of dividends and the mixed options activity suggest that the stock may not be ideal for dividend-focused investors. While there is potential for short-term momentum, the long-term outlook is less optimistic. Investors should consider the recent insider selling and the uncertain forecast before making any decisions. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.049648 |
| MSTL | 0.050478 |
| AutoETS | 0.050510 |
| AutoTheta | 0.052960 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 54% |
| H-stat | 2.90 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.686 |
| Excess Kurtosis | -0.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2010-07-01 |
| Last Dividend Date | 2007-04-02 |
| Debt to Equity Ratio | 44.39 |
| Revenue per Share | 13.863 |
| Market Cap | 4,622,755,328 |
| Trailing P/E | 37.82 |
| Forward P/E | 23.34 |
| Beta | 1.00 |
| Profit Margins | 46.42% |
| Website | https://www.ligand.com |
As of April 11, 2026, 3:06 p.m. EDT: Options speculators are showing mixed signals. The calls show higher open interest and volume on the out-of-the-money strikes, suggesting potential for upward movement, while the puts indicate significant open interest on the out-of-the-money strikes, indicating potential for downward movement. The IV is relatively high on some expirations, indicating uncertainty or heightened volatility expectations. The ATM strikes are heavily traded, suggesting a focus on the current price level.
| Date | Dividend | Yield % |
|---|---|---|
| 2007-04-03 | 9.357455 | 33.068783 |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2118118 |
| Address1 | 555 Heritage Drive |
| Address2 | Suite 200 |
| All Time High | 234.76 |
| All Time Low | 4.11728 |
| Ask | 235.68 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 257,530 |
| Average Daily Volume3 Month | 221,343 |
| Average Volume | 221,343 |
| Average Volume10Days | 257,530 |
| Beta | 1.003 |
| Bid | 228.49 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 51.442 |
| City | Jupiter |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 231.82 |
| Current Ratio | 22.225 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 234.31 |
| Day Low | 225.085 |
| Debt To Equity | 44.39 |
| Earnings Call Timestamp End | 1,772,112,600 |
| Earnings Call Timestamp Start | 1,772,112,600 |
| Earnings Timestamp | 1,772,112,600 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | 80,974,000 |
| Ebitda Margins | 0.30204 |
| Enterprise To Ebitda | 53.607 |
| Enterprise To Revenue | 16.192 |
| Enterprise Value | 4,340,775,424 |
| Eps Current Year | 8.6375 |
| Eps Forward | 9.93286 |
| Eps Trailing Twelve Months | 6.13 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,278,028,800 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 201.7588 |
| Fifty Day Average Change | 30.061203 |
| Fifty Day Average Change Percent | 0.14899574 |
| Fifty Two Week Change Percent | 121.181175 |
| Fifty Two Week High | 234.76 |
| Fifty Two Week High Change | -2.9399872 |
| Fifty Two Week High Change Percent | -0.012523374 |
| Fifty Two Week Low | 98.89 |
| Fifty Two Week Low Change | 132.93001 |
| Fifty Two Week Low Change Percent | 1.344221 |
| Fifty Two Week Range | 98.89 - 234.76 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 722,097,000,000 |
| Float Shares | 19,466,941 |
| Forward Eps | 9.93286 |
| Forward P E | 23.338696 |
| Free Cashflow | 87,089,504 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 47 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.64291 |
| Gross Profits | 172,356,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02457 |
| Held Percent Institutions | 1.0566001 |
| Implied Shares Outstanding | 19,941,141 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://investor.ligand.com/Investors/Investor-Overview/default.aspx |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,175,558,400 |
| Last Dividend Value | 9.357455 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,667,347,200 |
| Last Split Factor | 1,603:1000 |
| Long Business Summary | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida. |
| Long Name | Ligand Pharmaceuticals Incorporated |
| Market | us_market |
| Market Cap | 4,622,755,328 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_30820 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 124,453,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,630,931,174 |
| Number Of Analyst Opinions | 10 |
| Open | 226.1 |
| Operating Cashflow | 49,359,000 |
| Operating Margins | 0.33587003 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.53 |
| Phone | 858 550 7500 |
| Post Market Change | -0.08660889 |
| Post Market Change Percent | -0.037360404 |
| Post Market Price | 231.7334 |
| Post Market Time | 1,776,462,488 |
| Previous Close | 223.24 |
| Price Eps Current Year | 26.838785 |
| Price Hint | 2 |
| Price To Book | 4.5064344 |
| Price To Sales Trailing12 Months | 17.243488 |
| Profit Margins | 0.46423 |
| Quick Ratio | 21.827 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | 8.58 |
| Regular Market Change Percent | 3.8434 |
| Regular Market Day High | 234.31 |
| Regular Market Day Low | 225.085 |
| Regular Market Day Range | 225.085 - 234.31 |
| Regular Market Open | 226.1 |
| Regular Market Previous Close | 223.24 |
| Regular Market Price | 231.82 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 166,308 |
| Return On Assets | 0.02358 |
| Return On Equity | 0.13471 |
| Revenue Growth | 0.394 |
| Revenue Per Share | 13.863 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 19,941,141 |
| Shares Percent Shares Out | 0.075 |
| Shares Short | 1,495,607 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,378,177 |
| Short Name | Ligand Pharmaceuticals Incorpor |
| Short Percent Of Float | 0.090299994 |
| Short Ratio | 6.33 |
| Source Interval | 15 |
| State | FL |
| Symbol | LGND |
| Target High Price | 282.0 |
| Target Low Price | 220.0 |
| Target Mean Price | 246.7 |
| Target Median Price | 246.5 |
| Total Cash | 733,521,024 |
| Total Cash Per Share | 36.784 |
| Total Debt | 451,540,992 |
| Total Revenue | 268,087,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 6.13 |
| Trailing P E | 37.81729 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 181.60165 |
| Two Hundred Day Average Change | 50.218353 |
| Two Hundred Day Average Change Percent | 0.27653027 |
| Type Disp | Equity |
| Volume | 166,308 |
| Website | https://www.ligand.com |
| Zip | 33,458 |